426 related articles for article (PubMed ID: 23836557)
1. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia.
Yang G; Zhou Y; Liu X; Xu L; Cao Y; Manning RJ; Patterson CJ; Buhrlage SJ; Gray N; Tai YT; Anderson KC; Hunter ZR; Treon SP
Blood; 2013 Aug; 122(7):1222-32. PubMed ID: 23836557
[TBL] [Abstract][Full Text] [Related]
2. MYD88-independent growth and survival effects of Sp1 transactivation in Waldenstrom macroglobulinemia.
Fulciniti M; Amodio N; Bandi RL; Munshi M; Yang G; Xu L; Hunter Z; Tassone P; Anderson KC; Treon SP; Munshi NC
Blood; 2014 Apr; 123(17):2673-81. PubMed ID: 24622324
[TBL] [Abstract][Full Text] [Related]
3. MYD88 L265P mutation in Waldenstrom macroglobulinemia.
Poulain S; Roumier C; Decambron A; Renneville A; Herbaux C; Bertrand E; Tricot S; Daudignon A; Galiègue-Zouitina S; Soenen V; Theisen O; Grardel N; Nibourel O; Roche-Lestienne C; Quesnel B; Duthilleul P; Preudhomme C; Leleu X
Blood; 2013 May; 121(22):4504-11. PubMed ID: 23532735
[TBL] [Abstract][Full Text] [Related]
4. Novel approaches to targeting MYD88 in Waldenström macroglobulinemia.
Castillo JJ; Hunter ZR; Yang G; Treon SP
Expert Rev Hematol; 2017 Aug; 10(8):739-744. PubMed ID: 28617062
[TBL] [Abstract][Full Text] [Related]
5. Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status.
Cea M; Cagnetta A; Acharya C; Acharya P; Tai YT; Yang C; Lovera D; Soncini D; Miglino M; Fraternali-Orcioni G; Mastracci L; Nencioni A; Montecucco F; Monacelli F; Ballestrero A; Hideshima T; Chauhan D; Gobbi M; Lemoli RM; Munshi N; Treon SP; Anderson KC
Clin Cancer Res; 2016 Dec; 22(24):6099-6109. PubMed ID: 27287071
[TBL] [Abstract][Full Text] [Related]
6. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.
Treon SP; Xu L; Yang G; Zhou Y; Liu X; Cao Y; Sheehy P; Manning RJ; Patterson CJ; Tripsas C; Arcaini L; Pinkus GS; Rodig SJ; Sohani AR; Harris NL; Laramie JM; Skifter DA; Lincoln SE; Hunter ZR
N Engl J Med; 2012 Aug; 367(9):826-33. PubMed ID: 22931316
[TBL] [Abstract][Full Text] [Related]
7. CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenström macroglobulinaemia cells.
Cao Y; Hunter ZR; Liu X; Xu L; Yang G; Chen J; Tsakmaklis N; Kanan S; Castillo JJ; Treon SP
Br J Haematol; 2015 Mar; 168(5):701-7. PubMed ID: 25371371
[TBL] [Abstract][Full Text] [Related]
8. Rare Circulating Cells in Familial Waldenström Macroglobulinemia Displaying the MYD88 L265P Mutation Are Enriched by Epstein-Barr Virus Immortalization.
Pertesi M; Galia P; Nazaret N; Vallée M; Garderet L; Leleu X; Avet-Loiseau H; Foll M; Byrnes G; Lachuer J; McKay JD; Dumontet C
PLoS One; 2015; 10(9):e0136505. PubMed ID: 26352266
[TBL] [Abstract][Full Text] [Related]
9. HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib.
Yang G; Buhrlage SJ; Tan L; Liu X; Chen J; Xu L; Tsakmaklis N; Chen JG; Patterson CJ; Brown JR; Castillo JJ; Zhang W; Zhang X; Liu S; Cohen P; Hunter ZR; Gray N; Treon SP
Blood; 2016 Jun; 127(25):3237-52. PubMed ID: 27143257
[TBL] [Abstract][Full Text] [Related]
10. MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction.
Xu L; Hunter ZR; Yang G; Zhou Y; Cao Y; Liu X; Morra E; Trojani A; Greco A; Arcaini L; Varettoni M; Brown JR; Tai YT; Anderson KC; Munshi NC; Patterson CJ; Manning RJ; Tripsas CK; Lindeman NI; Treon SP
Blood; 2013 Mar; 121(11):2051-8. PubMed ID: 23321251
[TBL] [Abstract][Full Text] [Related]
11. IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenström macroglobulinemia/lymphoplasmacytic lymphomas.
Gachard N; Parrens M; Soubeyran I; Petit B; Marfak A; Rizzo D; Devesa M; Delage-Corre M; Coste V; Laforêt MP; de Mascarel A; Merlio JP; Bouabdhalla K; Milpied N; Soubeyran P; Schmitt A; Bordessoule D; Cogné M; Feuillard J
Leukemia; 2013 Jan; 27(1):183-9. PubMed ID: 22944768
[TBL] [Abstract][Full Text] [Related]
12. [Lymphoplasmacytic lymphoma accompanied by transformed diffuse large B-cell lymphoma with the MYD88
Kida T; Tanimura A; Ono A; Matsui T; Honma K; Fujita J; Maeda T; Shibayama H; Oritani K; Morii E; Kanakura Y
Rinsho Ketsueki; 2017; 58(2):155-160. PubMed ID: 28321094
[TBL] [Abstract][Full Text] [Related]
13. Bruton Tyrosine Kinase Inhibition: an Effective Strategy to Manage Waldenström Macroglobulinemia.
Tawfiq RK; Abeykoon JP; Kapoor P
Curr Hematol Malig Rep; 2024 Jun; 19(3):120-137. PubMed ID: 38536576
[TBL] [Abstract][Full Text] [Related]
14. Clone-specific MYD88 L265P and CXCR4 mutation status can provide clinical utility in suspected Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
Burnworth B; Wang Z; Singleton TP; Bennington A; Fritschle W; Bennington R; Brodersen LE; Wells DA; Loken MR; Zehentner BK
Leuk Res; 2016 Dec; 51():41-48. PubMed ID: 27890075
[TBL] [Abstract][Full Text] [Related]
15. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia.
Treon SP; Cao Y; Xu L; Yang G; Liu X; Hunter ZR
Blood; 2014 May; 123(18):2791-6. PubMed ID: 24553177
[TBL] [Abstract][Full Text] [Related]
16. MYD88 mutant lymphoplasmacytic lymphoma/Waldenström macroglobulinemia has distinct clinical and pathological features as compared to its mutation negative counterpart.
Patkar N; Subramanian PG; Deshpande P; Ghodke K; Tembhare P; Mascarenhas R; Muranjan A; Chaudhary S; Bagal B; Gujral S; Sengar M; Menon H
Leuk Lymphoma; 2015 Feb; 56(2):420-5. PubMed ID: 24828863
[TBL] [Abstract][Full Text] [Related]
17. Lymphoplasmacytic Lymphoma With a Non-IgM Paraprotein Shows Clinical and Pathologic Heterogeneity and May Harbor MYD88 L265P Mutations.
King RL; Gonsalves WI; Ansell SM; Greipp PT; Frederick LA; Viswanatha DS; He R; Kyle RA; Gertz MA; Kapoor P; Morice WG; Howard MT
Am J Clin Pathol; 2016 Jun; 145(6):843-51. PubMed ID: 27329639
[TBL] [Abstract][Full Text] [Related]
18. [Evaluation of clinical characteristics, MYD88(L265P) mutation, CXCR4(WHIM) mutation and prognosis in Waldenström macroglobulinemia: A single center retrospective study of 93 patients].
Cao XX; Meng Q; Cai H; Mao YY; Duan MH; Zhu TN; Zhang W; Han B; Zhuang JL; Cai HC; Chen M; Feng J; Han X; Zhang Y; Yang C; Zhang L; Zhou DB; Li J
Zhonghua Xue Ye Xue Za Zhi; 2017 Jun; 38(6):494-498. PubMed ID: 28655092
[No Abstract] [Full Text] [Related]
19. Interleukin-1 Receptor-Associated Kinase (IRAK) Signaling in Kaposi Sarcoma-Associated Herpesvirus-Induced Primary Effusion Lymphoma.
Seltzer J; Moorad R; Schifano JM; Landis JT; Dittmer DP
J Virol; 2020 May; 94(10):. PubMed ID: 32161170
[TBL] [Abstract][Full Text] [Related]
20. Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease.
Cao XX; Meng Q; Cai H; He TH; Zhang CL; Su W; Sun J; Li Y; Xu W; Zhou DB; Li J
Ann Hematol; 2017 Jun; 96(6):971-976. PubMed ID: 28280994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
